Applies to Employer and ACA Marketplace plans.
Covered with requirementsQualification pathways
You can qualify through any one of these.
Moderate-to-severe OSA in adults with obesity
All of:
- Age ≥ 18 years
- BMI ≥ 30 kg/m2 (obesity)
- Diagnosis of moderate-to-severe OSA confirmed by PSG or HSAT (AHI/REI ≥ 15 events/hour for moderate; ≥ 30 for severe)
Plus any one of:
- Not currently receiving PAP therapy (can receive Zepbound with or without PAP per SURMOUNT-OSA trials)
- Currently receiving PAP therapy (SURMOUNT-OSA Trial 2 included PAP users)
Documentation to bring
- Diagnosis of moderate-to-severe OSA confirmed by polysomnography (PSG) or home sleep apnea test (HSAT) with AHI or REI ≥ 15 events/hour
- Baseline BMI documentation ≥ 30 kg/m2
- Sleep study results (PSG or HSAT report) documenting AHI/REI severity
- Documentation of reduced-calorie diet and increased physical activity as adjunct
Not covered when
- Craniofacial abnormalities affecting respiration (per SURMOUNT-OSA exclusion criteria cited in document)
- Predominantly central or mixed sleep apnea (≥ 50% central or mixed apneas/hypopneas)
- Cheyne-Stokes respiration
- Obesity hypoventilation syndrome
- Daytime hypercapnia
- Coadministration with other tirzepatide-containing products not recommended
- Coadministration with any GLP-1 receptor agonist not recommended
- Pregnancy
Policy note: OSA indication requires obesity (BMI ≥ 30) per FDA label. Moderate-to-severe OSA defined as AHI ≥ 15 events/hour (moderate 15-29, severe ≥ 30). The SURMOUNT-OSA program enrolled both PAP-naive (Trial 1) and PAP-using (Trial 2) patients; PAP trial is NOT required as a prerequisite. AHI from PSG is the preferred diagnostic index; REI from HSAT is acceptable but may underestimate severity. RDI may identify arousal-based disease not fully captured by AHI/REI. Document extensively discusses OSA diagnostic methodology (PSG vs HSAT, AHI vs REI vs RDI, hypopnea scoring rules) as clinical rationale. The OSA ahi min of 15 is inferred from 'moderate-to-severe' OSA definition per AASM standard referenced in the document; the document does not explicitly state a specific AHI threshold as a PA requirement but references moderate-to-severe as the qualifying severity. PAP therapy use is not required prior to Zepbound; patients on PAP or not on PAP may qualify.
Policy effective April 20, 2026 · verified June 2, 2026 · source: Albp Weight Management Paql Prog Sum · View policy document (PDF)